FDA Approves Bimzelx for Hidradenitis Suppurativa
Approval based on phase 3 trials showing clinical response at 16 weeks, with sustained benefit at 48 weeks
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.